News

AgroSpheres Named on Both the World’s Top GreenTech Companies 2025 and America’s Top GreenTech Companies 2025 Lists by TIME Magazine

AgroSpheres has been named on both the World’s Top GreenTech Companies 2025 and America’s Top GreenTech Companies 2025 lists. These prestigious awards are presented by TIME and Statista Inc., the leading statistics portal and industry ranking provider. The award lists were announced on March 25th, 2025, and can be viewed on TIME’s website.

Statista ranked the winners based on three evaluation criteria:

  • Positive environmental impact: The scoring is based on impact data such as the quality and impact of their product/service portfolio, as well as the expertise of their leadership team provided by HolonIQ
  • Financial strength: The scoring is based on the analysis of financial data points e.g., revenue, employee or funding information
  • Innovation drive: The scoring is based on the Patent Asset Index featured in LexisNexis® Intellectual Property Solutions

“Being recognized by TIME as one of the top GreenTech companies in both the U.S. and globally is a testament to the power of science-driven innovation in reshaping agriculture and our strong business fundamentals,” said Payam Pourtaheri, Co-Founder and CEO of AgroSpheres. “We have built a solid financial foundation to support the rapid commercialization of our bio-based solutions, ensuring long-term impact for growers and the environment. This recognition reinforces our mission to lead the way in the bio-based revolution.”

“Innovation drive and impact go hand in hand,” added Ameer Shakeel, AgroSpheres’ Co-Founder and CTO. “We have built an end-to-end technology platform, rooted in cutting-edge science, novel active ingredients and a strong intellectual property portfolio. Our advancements in encapsulation and delivery technologies are paving the way for greener, more effective crop protection solutions across the industry. As we scale our operations to commercialization, this honor from TIME highlights the growing momentum behind sustainable agriculture worldwide.”

In support of the research, Statista gathered data from company applications, annual reports, media monitoring, and other public sources. Additionally, Statista worked with specialized data partners HolonIQ and LexisNexis® Intellectual Property Solutions to further strengthen the data quality.

Statista publishes hundreds of worldwide industry rankings and company listings with high-profile media partners. This research and analysis service is based on the success of statista.com, the leading data and business intelligence portal that provides statistics, relevant business data, and various market and consumer studies and surveys.

Read more here.

Recent News

10/22/2025

Virginia Catalyst Announces Round 19 of Grant Funding

The Virginia Catalyst announced today that it is accepting letters of intent (LOI) for Grant Round 19 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “We at the Virginia Catalyst are pleased to provide funding in support of the Governor’s

10/21/2025

SRI multi-party team selected as an awardee by ARPA-H to develop at-home screening for ≥30 types of cancers

SRI, along with research partners Foothold Labs and Triple Ring Technologies and commercial partner Beacon Dx Health, has been awarded up to $34 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop technology as part of the POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in Oncology) program. This pioneering program

10/21/2025

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead product candidate, QRX003, for the treatment of Netherton Syndrome. The designation follows previously granted Orphan